3.545

1.93% -0.075

Xeris Biopharma Holdings Inc (XERS)

Overview News Price History Option Chain Financials Discussions Forecast

Xeris Biopharma Holdings Inc stock is traded at $3.545, with a volume of 801.76K. It is down -1.93% in the last 24 hours and up +5.97% over the past month. Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Previous Close:

$3.62

Open:

$3.62

24h Volume:

801.76K

Relative Volume:

0.50

Market Cap:

$539.67M

Revenue:

$181.41M

Net Income/Loss:

$-59.56M

P/E Ratio:

-8.4405

EPS:

-0.42

Net Cash Flow:

$-38.83M

1W Performance:

-0.28%

1M Performance:

+5.97%

6M Performance:

+66.67%

1Y Performance:

+34.98%

1-Day Range:

$3.52

$3.64

1-Week Range:

$3.4752

$3.73

52-Week Range:

$1.69

$3.87

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Name

Xeris Biopharma Holdings Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

844-445-5704

Address

1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL

Employee

377

Twitter

@XerisPharma

Next Earnings Date

2024-12-08

Latest SEC Filings

XERS's Discussions on Twitter

Compare XERS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XERS Xeris Biopharma Holdings Inc	3.545	539.67M	181.41M	-59.56M	-38.83M	-0.42
VRTX Vertex Pharmaceuticals Inc	473.85	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	715.27	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	651.13	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	274.65	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.63	28.75B	3.30B	-501.07M	1.03B	-2.1146

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Mar-28-24	Initiated	Oppenheimer	Outperform
Aug-28-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Craig Hallum	Buy
Nov-17-21	Initiated	SVB Leerink	Outperform
Oct-29-21	Initiated	H.C. Wainwright	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-18-20	Initiated	Piper Sandler	Overweight
Jul-16-18	Initiated	Jefferies	Buy
Jul-16-18	Initiated	Leerink Partners	Outperform
Jul-16-18	Initiated	RBC Capital Mkts	Outperform

View All

Xeris Biopharma Holdings Inc Stock (XERS) Latest News

Feb 05, 2025

Stock Performance Spotlight: Xeris Biopharma Holdings Inc (XERS) Ends the Day at 3.64, Up by 1.39 - The Dwinnex

Feb 05, 2025

Xeris to Participate in Upcoming Investor Conferences - BioSpace

Feb 05, 2025

Strategic Moves: Xeris Biopharma Takes Center Stage at Elite Healthcare Investment Forums - StockTitan

Feb 05, 2025

A year in review: Xeris Biopharma Holdings Inc (XERS)’s performance in the last year - US Post News

Feb 05, 2025

SG Americas Securities LLC Raises Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Feb 05, 2025

Feb 04, 2025

Perhaps timely catching Xeris Biopharma Holdings Inc (XERS) would be a good idea - SETE News

Feb 04, 2025

Piper Sandler downgrades Xeris Biopharma Holdings Inc (XERS) rating to a Neutral - Knox Daily

Feb 04, 2025

Jan 30, 2025

Some Shareholders Feeling Restless Over Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) P/S Ratio - Simply Wall St

Jan 30, 2025

Jan 25, 2025

JPMorgan Chase & Co. Acquires 67,557 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Jan 25, 2025

Jan 22, 2025

Xeris Biopharma Holdings Inc (NASDAQ: XERS) Down -1.47% This Year: What To Expect Next - Stocks Register

Jan 22, 2025

Jan 21, 2025

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness - Beloit Daily News

Jan 21, 2025

Jan 16, 2025